Drug Company’s Libel Lawsuit Against Scientists Dismissed
From yesterday’s decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt:
Cassava Sciences, Inc. (“Cassava”) is a biotechnology company that is conducting clinical trials for an Alzheimer’s drug called simufilam. Following the second phase of the simufilam clinical trials, multiple short sellers, most of them scientists, published concerns about the integrity of the clinical trials and other studies related to simufilam. They sent letters to the Food and Drug Administration (the “FDA”) that painstakingly analyzed published results, data, and methodology, published presentations aimed at investors that summarized the letters and analyzed Cassava’s public representations, and posted hundreds of tweets, which were, by their nature, much less rigorous.
Cassava vigorously disagreed with the concerns expressed by the short sellers. Members of the scientific community in Cassava’s position have a variety of options. They can publish a thorough, factually supported rebuttal. They can facilitate replication of their results by a neutral, unaffiliated lab. They can invite the scientists expressing concerns to review their unpublished underlying data. Here, Cassava is pursuing another approach: a lawsuit against the people who have critiqued its scientific findings….
B
Article from Reason.com
The Reason Magazine website is a go-to destination for libertarians seeking cogent analysis, investigative reporting, and thought-provoking commentary. Championing the principles of individual freedom, limited government, and free markets, the site offers a diverse range of articles, videos, and podcasts that challenge conventional wisdom and advocate for libertarian solutions. Whether you’re interested in politics, culture, or technology, Reason provides a unique lens that prioritizes liberty and rational discourse. It’s an essential resource for those who value critical thinking and nuanced debate in the pursuit of a freer society.